Core Insights - HCW Biologics Inc. has received a total upfront license fee of $7.0 million from Beijing Trimmune Biotech Co., Ltd., which includes a cash payment of $3.5 million and an in-kind payment of a transferable equity interest valued at $3.5 million [1][3] - The initiation of a Phase 1 clinical study in China for HCW11-006 is expected in the first half of 2027 [1] - HCW Biologics retains a "free" option to reclaim rights to the Americas territory after the Phase 1 clinical trial in China [1] Company Overview - HCW Biologics is a U.S.-based biopharmaceutical company focused on developing novel fusion immunotherapies for autoimmune diseases, cancer, and senescence-associated dysplasia [4] - The company's lead product candidate for autoimmune disorders is HCW9302, currently in a Phase 1 clinical study for alopecia areata [4] - HCW Biologics has identified two preclinical candidates, HCW11-018b and HCW11-040, which are designed to address specific challenges in treating solid tumors and enhancing immune responses [4] Licensing and Development - Trimmune, formed by WY Biotech Co., Ltd. and HCW Biologics, is responsible for the development and commercialization of HCW11-006 [2] - The licensing agreement allows HCW Biologics to receive significant milestone payments and double-digit royalties on future product sales [3] - Trimmune has the option to license exclusive regional rights for HCW9302 in China, with additional payments due to HCW Biologics if this option is exercised [3]

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells manufactured using HCW9206 showed strong anti-tumor activity in leukemia and enhanced antiviral potency in HIV suggesting potential for curative outcomes Employing HCW9206 as a manufacturing reagent may lower the cost of CAR-T manufacturing MIRAMAR, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or ...

Core Insights - HCW Biologics Inc. has regained compliance with Nasdaq listing rules, allowing continued access to public capital markets for advancing its immunotherapeutic drugs [1][2] Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies aimed at treating diseases linked to chronic inflammation, particularly age-related and senescence-associated diseases [2] - The company's lead product candidate, HCW9302, is a first-in-kind interleukin-2 fusion molecule currently in a Phase 1 clinical study for alopecia areata [2] Product Pipeline - HCW Biologics has identified two preclinical lead product candidates: - HCW11-018b ("Big BiTE"), a tetra-valent T-cell engager designed to improve manufacturability and safety for treating solid tumors [2] - HCW11-040, a pembrolizumab-based immune checkpoint inhibitor enhanced with additional moieties to neutralize TGF-β and activate immune responses [2] Business Development - The company has entered into two licensing agreements for exclusive worldwide rights to some proprietary molecules, indicating a focus on business development as part of its clinical strategy [2]

Core Viewpoint - HCW Biologics Inc. has regained compliance with Nasdaq listing rules, allowing the company to continue accessing public markets for capital to advance its immunotherapy drugs aimed at treating autoimmune diseases and cancer [1][2]. Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat diseases associated with chronic inflammation, particularly age-related and senescence-associated diseases [2]. - The company's lead product candidate, HCW9302, is a first-in-kind interleukin-2 fusion molecule currently in a Phase 1 clinical study for alopecia areata [2]. - HCW Biologics has also identified two preclinical candidates: HCW11-018b, a tetra-valent T-cell engager, and HCW11-040, a pembrolizumab-based immune checkpoint inhibitor designed to enhance efficacy by neutralizing TGF-β [2]. Clinical Development and Strategy - The company is focusing on business development programs and has entered into two licensing agreements for exclusive worldwide rights to some proprietary molecules [2]. - The immunotherapeutics developed by HCW Biologics are believed to have the potential to fundamentally change the treatment landscape for various diseases linked to chronic inflammation [2].

Core Viewpoint - HCW Biologics Inc. has announced a follow-on offering of 2,477,292 units at a price of $0.6055 per unit, aimed at funding clinical development and general corporate purposes [1][2]. Group 1: Offering Details - The offering consists of units that include one share of common stock (or pre-funded warrant) and one warrant, each with an exercise price of $0.6055, exercisable upon shareholder approval [1]. - The gross proceeds from the offering are expected to be approximately $1.5 million before deducting fees and expenses [2]. - The closing of the offering is anticipated to occur on or about February 19, 2026, subject to customary closing conditions [1]. Group 2: Existing Warrants - The company has negotiated to reduce the exercise price of existing warrants from $2.41 to $0.6055 per share, pending shareholder approval [3]. Group 3: Company Overview - HCW Biologics is a clinical-stage biopharmaceutical company focused on developing immunotherapies targeting chronic inflammation and related diseases [6]. - The lead product candidate, HCW9302, is being evaluated in a Phase 1 clinical trial for autoimmune diseases [7]. - The company has developed over 50 molecules using its TRBC platform, which aims to create immunotherapeutics for various disease indications, including cancer and autoimmune diseases [6][7].

Table of Contents As filed with the Securities and Exchange Commission on February 17, 2026 Registration No. 333-293396 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HCW BIOLOGICS INC. (Exact name of Registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 2834 82-5024477 Primary Standard Industrial Classification Code Number (I.R.S. Employer Ident ...

As filed with the Securities and Exchange Commission on February 13, 2026 Registration No. 333-293396 Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HCW BIOLOGICS INC. (Exact name of Registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 2834 82-5024477 Primary Standard Industrial Classification Code Number 2929 N Commerce Parkway Miramar, FL 3 ...

Core Insights - HCW Biologics has entered into an exclusive worldwide license agreement with WY Biotech for the development and commercialization of the proprietary molecule HCW11-006, valued at $7 million [1][2] - The Phase 1 clinical study for HCW11-006 is expected to begin in the first half of 2027, targeting solid tumors [3][4] - HCW Biologics retains a royalty-free option to reclaim rights for the Americas territory after the Phase 1 trial [4] Company Overview - HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies targeting chronic inflammation and related diseases [6] - The company has developed over 50 molecules using its TRBC drug development platform, which aims to create immunotherapeutics for various diseases, including cancer and autoimmune disorders [6][7] Partnership and Financials - A new entity, Beijing Trimmune Biotech Co., Ltd., has been established to manage the development and commercialization of HCW11-006, backed by CITIC Medical Fund and TigerYeah Capital Fund [2][3] - Trimmune has initiated payment of $1.75 million as part of a $3.5 million upfront cash license fee to HCW Biologics, with additional milestone payments and royalties expected from future sales [3][4] Development Strategy - Trimmune plans to leverage the expertise of HCW Biologics and its own management team to advance the clinical development of HCW11-006, aiming to address significant unmet medical needs in the Chinese market [2][5] - The collaboration is expected to facilitate the exploration of business development opportunities with multinational corporations once key clinical data is generated [4][5]

Table of Contents As filed with the Securities and Exchange Commission on February 11, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HCW BIOLOGICS INC. (Exact name of Registrant as specified in its charter) Delaware 2834 82-5024477 (State or Other Jurisdiction of Incorporation or Organization) Primary Standard Industrial Classification Code Number 2929 N Commerce Parkway Miramar, FL 33025 (9 ...

FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HCW BIOLOGICS INC. Table of Contents As filed with the Securities and Exchange Commission on January 9, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Exact name of Registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 2834 82-5024477 Primary Standard Industrial Classification Code Number 2929 N Commerce Parkway Miramar, FL 33025 (954 ...